Target intelligence / Profile preview

Cardiac mitochondrial fatty acid oxidation pathway (FAO)

Target
FAO
Molecular classification
Enzyme, Transporter, Other
01

Overview

The cardiac mitochondrial fatty acid oxidation (FAO) pathway is the primary metabolic route for energy production in the healthy heart, supplying the majority of ATP required for contraction (Lopaschuk et al., 2010). This pathway involves the transport of long-chain fatty acids into the mitochondria via the carnitine shuttle and their subsequent degradation through the beta-oxidation cycle (Stanley et al., 2005). In pathological states such as heart failure and myocardial ischemia, the heart's reliance on FAO can become inefficient, leading to increased oxygen consumption and the accumulation of potentially toxic lipid metabolites (Fillmore et al., 2014). Therapeutic strategies targeting this pathway aim to partially inhibit FAO enzymes, such as 3-ketoacyl-CoA thiolase or carnitine palmitoyltransferase 1, to shift the heart's substrate preference toward glucose oxidation (Kantor et al., 2000). This metabolic switch improves cardiac efficiency by increasing the amount of ATP produced per molecule of oxygen consumed, thereby providing a cardioprotective effect in ischemic and failing myocardium. Drugs like trimetazidine and perhexiline have been utilized to modulate this pathway, showing benefits in reducing anginal symptoms and improving exercise tolerance. However, targeting this pathway requires careful management due to potential side effects like drug-induced parkinsonism or hepatotoxicity. Overall, the cardiac FAO pathway remains a significant area of interest for developing metabolic therapies for cardiovascular diseases.

Other names
Mitochondrial fatty acid beta-oxidationCardiac fatty acid oxidationMyocardial fatty acid metabolismBeta-oxidation pathway
02

Mechanism of action

Partial inhibition of mitochondrial enzymes such as 3-ketoacyl-CoA thiolase (3-KAT) or transport proteins like carnitine palmitoyltransferase 1 (CPT1) to reduce fatty acid oxidation and reciprocally increase glucose oxidation, enhancing myocardial oxygen efficiency (Kantor et al., 2000; Lopaschuk et al., 2010).

03

Biological functions

Other
04

Disease associations

Cardiovascular disease
05

Safety considerations

Drug-induced parkinsonismHepatotoxicityPeripheral neuropathyMetabolic derangement
06

Interacting drugs

Trimetazidine

4 more in the full profile.

07

Biomarkers

Plasma acylcarnitine levelsBrain natriuretic peptide (BNP)C-11 palmitate PET imagingMyocardial oxygen consumption (MVO2)

Beyond the preview

Go deeper on Cardiac mitochondrial fatty acid oxidation pathway (FAO).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiac mitochondrial fatty acid oxidation pathway (FAO).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call